Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, announced the pricing of its initial public offering of 3,666,667 shares of common stock at a public offering price of $15.00 per share.
Ayala Pharmaceuticals Announces Pricing of Initial Public Offering
